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1. INTRODUCTION {#dom13866-sec-0005}
===============

Early achievement of sustained glycaemic control is a key component of the effective management of patients with type 2 diabetes (T2D), given the well‐established increased risk of diabetes‐related complications associated with hyperglycaemia.[1](#dom13866-bib-0001){ref-type="ref"}, [2](#dom13866-bib-0002){ref-type="ref"}, [3](#dom13866-bib-0003){ref-type="ref"} The UK Prospective Diabetes Study demonstrated that an absolute reduction in glycated haemoglobin (HbA1c) level of 1.0% is associated with risk reductions of 21%, 14% and 37% for diabetes‐related death, myocardial infarction and microvascular complications, respectively.[1](#dom13866-bib-0001){ref-type="ref"} In a 10‐year post‐interventional follow‐up of the study cohort, early attainment of glycaemic control was associated with long‐term microvascular benefits,[4](#dom13866-bib-0004){ref-type="ref"} and there is also evidence that early attainment of tight glycaemic control is predictive of long‐term glycaemic control.[5](#dom13866-bib-0005){ref-type="ref"}

On the basis of this evidence, most clinical guidelines advocate a target HbA1c level of either \<7.0% or ≤6.5% depending on additional patient‐specific factors such as age, duration of diabetes, comorbidities, and risk of hypoglycaemia.[6](#dom13866-bib-0006){ref-type="ref"}, [7](#dom13866-bib-0007){ref-type="ref"}, [8](#dom13866-bib-0008){ref-type="ref"}, [9](#dom13866-bib-0009){ref-type="ref"}, [10](#dom13866-bib-0010){ref-type="ref"} Treatment intensification is recommended when patients remain above their HbA1c targets for \>3 months after the last intervention. Despite these recommendations, available data, mainly from Europe and North America, indicate poor attainment of glycaemic targets and infrequent implementation of timely treatment intensification.[11](#dom13866-bib-0011){ref-type="ref"}, [12](#dom13866-bib-0012){ref-type="ref"}, [13](#dom13866-bib-0013){ref-type="ref"}, [14](#dom13866-bib-0014){ref-type="ref"}, [15](#dom13866-bib-0015){ref-type="ref"}, [16](#dom13866-bib-0016){ref-type="ref"} Moreover, real‐world data on the management of T2D are scarce in many low‐ and middle‐income countries, in which the rising disease prevalence is a concern.

DISCOVER is a 3‐year, global, prospective, observational study programme designed to describe the disease management patterns and a broad range of associated outcomes, including glycaemic control, in patients with T2D initiating a second‐line glucose‐lowering treatment (defined as adding a glucose‐lowering drug or switching between therapies) after first‐line (defined as the first pharmacological treatment given for the disease) oral therapy in routine clinical practice.[17](#dom13866-bib-0017){ref-type="ref"}, [18](#dom13866-bib-0018){ref-type="ref"} The aim of the present analysis was to describe the level of glycaemic control in participants in DISCOVER at initiation of second‐line glucose‐lowering therapy. Factors associated with poor glycaemic control were also assessed.

2. MATERIALS AND METHODS {#dom13866-sec-0006}
========================

The methods for the DISCOVER study programme have been reported in detail elsewhere[17](#dom13866-bib-0017){ref-type="ref"}, [18](#dom13866-bib-0018){ref-type="ref"} and are summarized below.

2.1. Study design {#dom13866-sec-0007}
-----------------

The global DISCOVER study programme comprises two similar, 3‐year, non‐interventional, prospective studies conducted simultaneously in 38 countries; DISCOVER (NCT02322762) in 37 countries and J‐DISCOVER (NCT02226822) in Japan. Included countries are divided into regions according to the World Health Organization (WHO) categories: Africa (Algeria and South Africa); the Americas (Argentina, Brazil, Canada, Colombia, Costa Rica, Mexico and Panama); South‐East Asia (India and Indonesia); Europe (Austria, Czech Republic, Denmark, France, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and Turkey); Eastern Mediterranean (Bahrain, Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia and United Arab Emirates); and the Western Pacific region (Australia, China, Japan, Malaysia, South Korea and Taiwan). The study protocols were approved by the appropriate clinical research ethics committees in each participating country, and the relevant institutional review boards at each site. The protocols comply with the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice, and the local regulations for clinical research.

2.2. Site and investigator selection {#dom13866-sec-0008}
------------------------------------

Characteristics of physicians and practices involved in the management of patients with T2D were assessed in each participating country, before the start of the study, by combining data from peer‐reviewed articles, information from reports published by organizations such as the WHO, and insights from key local diabetes experts who acted as national coordinating investigators.[19](#dom13866-bib-0019){ref-type="ref"} The proportions of different types of physicians (primary care physicians, diabetologists, endocrinologists, cardiologists and other specialists) and practices (primary care centres, specialized diabetes centres and different types of hospitals), as well as the location of practices (urban vs rural and geographical distribution within a country), treating patients with T2D in each country were collated. A list of sites that would match these characteristics as closely as possible was then established for each country, and all sites were invited to participate in the study.[19](#dom13866-bib-0019){ref-type="ref"}

2.3. Patient recruitment {#dom13866-sec-0009}
------------------------

Full inclusion and exclusion criteria are shown in Table [S1](#dom13866-supitem-0001){ref-type="supplementary-material"}. Patients aged \>18 years (\>20 years in Japan) with T2D, who were initiating a second‐line glucose‐lowering therapy were eligible for inclusion if they were not pregnant, were not undergoing dialysis, did not have a history of renal transplant, and if their first‐line therapy was not an injectable agent, a herbal remedy, or a natural medicine alone. The study protocol stated that investigating physicians should invite consecutive eligible patients to participate in the study. All participating patients provided signed informed consent.

2.4. Data collection {#dom13866-sec-0010}
--------------------

Data were collected at initiation of second‐line glucose‐lowering therapy using a standardized case report form and transferred to a central database via a web‐based data capture system. Some data were extracted from existing electronic health records in Canada, Denmark, France, Norway and Sweden; in these countries, an abbreviated case report form was used.

Variables collected included: physician and site characteristics; patient socio‐economic demographics; physiological characteristics including height, weight and seated blood pressure; laboratory test results including HbA1c level and/or fasting plasma glucose (FPG) at the time of treatment change; change in glucose‐lowering therapies and reason(s) for change; comorbidities, including diabetes‐related microvascular and macrovascular diseases; and co‐medications. In line with the observational nature of the study, clinical variables, such as HbA1c levels, were measured and recorded in accordance with routine clinical practice; data collection was not mandatory for any of the clinical variables.

2.5. Statistical analysis {#dom13866-sec-0011}
-------------------------

For the present analysis, patients from China (n = 1293) were excluded because complete data were not available at the time of publication; therefore, the total number of patients included in the analysis was 14 699 (91.9% of the total DISCOVER population). Descriptive data are presented as numbers and percentages for categorical variables. For continuous variables, mean (SD), median (interquartile range \[IQR\]), and across‐region ranges (ARRs) are reported, where appropriate.

Factors associated with poor glycaemic control were assessed in patients with available HbA1c levels using hierarchical logistic regression models, with country as a random effect. HbA1c was modelled as a dichotomous variable (≤7.0% vs \>7.0%, ≤8.0% vs \>8.0%, and ≤9.0% vs \>9.0%) with the following additional variables included in the models: age; sex; education level; smoking status; body mass index (BMI); systolic blood pressure (SBP); time since diagnosis of T2D (used as a proxy for diabetes duration); use of co‐medications (angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, diuretics, β‐blockers, statins and acetylsalicylic acid); first‐line glucose‐lowering therapy; history of microvascular complications (including nephropathy \[presence of chronic kidney disease and/or albuminuria\], retinopathy \[history of retinopathy or retinal laser photocoagulation\], and neuropathy \[autonomic neuropathy, peripheral neuropathy and erectile dysfunction\]); and history of macrovascular complications (including coronary artery disease \[history of coronary artery disease, angina, myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting\], cerebrovascular disease \[stroke, transient ischaemic attack, carotid artery stenting and carotid endarterectomy\], peripheral artery disease \[history of peripheral artery disease including revascularization procedures, diabetic foot, and amputation\], heart failure, and implantable cardioverter defibrillator use). Gross national income was also included in the models, using 2016 data from the World Bank (Classification of DISCOVER countries by gross national income in 2016 is shown in Figure [S1](#dom13866-supitem-0001){ref-type="supplementary-material"}).[20](#dom13866-bib-0020){ref-type="ref"} Complete data were available for 81.7% of patients included in the model. Separate models were also used to assess the association between receiving education on diabetes management in the past year and having poor glycaemic control. These models did not include data from Japan because data for this variable were not collected in this country. Multiple imputation was used in multivariable analyses to account for unreported data and missing values. Imputation was carried out using IVEware (University of Michigan). All other statistical analyses were carried out using the SAS statistical software system (SAS Institute, Inc., Cary, North Carolina).

3. RESULTS {#dom13866-sec-0012}
==========

The demographics and characteristics of the DISCOVER cohort (N = 15 992) at initiation of second‐line therapy have been reported previously.[21](#dom13866-bib-0021){ref-type="ref"} Characteristics of patients with available HbA1c data (N = 11 891) are presented in Table [1](#dom13866-tbl-0001){ref-type="table"}. Overall, most patients were Asian (43.1%) or white (30.0%), and 56.0% of participants were men. The mean (SD) age was 57.7 (12.1) years and the mean (SD) BMI and time since diagnosis of T2D were 29.4 (6.0) kg/m^2^ and 5.7 (5.3) years, respectively.

###### 

Patient characteristics, overall and according to glycated haemoglobin category

                                                                                   Total          HbA1c \<7.0%   HbA1c 7.0% to \<8.0%   HbA1c 8.0% to \<9.0%   HbA1c ≥9.0%
  -------------------------------------------------------------------------------- -------------- -------------- ---------------------- ---------------------- --------------
  Men, n (%)                                                                       6657 (56.0)    1134 (54.8)    2129 (55.5)            1585 (56.5)            1809 (57.0)
  Gender data missing                                                              4              2              2                      0                      0
  Self‐reported ethnicity, n (%)                                                                                                                               
  White                                                                            3403 (30.0)    581 (29.8)     1195 (32.6)            829 (30.8)             798 (26.2)
  Black                                                                            128 (1.1)      22 (1.1)       42 (1.1)               22 (0.8)               42 (1.4)
  Asian                                                                            4892 (43.1)    992 (50.8)     1653 (45.1)            1016 (37.7)            1231 (40.4)
  Hispanic                                                                         661 (5.8)      110 (5.6)      192 (5.2)              154 (5.7)              205 (6.7)
  Arabic                                                                           2019 (17.8)    209 (10.7)     509 (13.9)             610 (22.7)             691 (22.7)
  Mixed                                                                            110 (1.0)      14 (0.7)       33 (0.9)               19 (0.7)               44 (1.4)
  Other                                                                            142 (1.3)      23 (1.2)       40 (1.1)               42 (1.6)               37 (1.2)
  Missing                                                                          536            120            176                    112                    128
  Time in formal education, n (%)                                                                                                                              
  No formal education                                                              322 (3.0)      27 (1.5)       93 (2.7)               82 (3.2)               120 (4.2)
  Primary (1--6 y)                                                                 1609 (14.9)    230 (12.6)     460 (13.2)             391 (15.1)             528 (18.3)
  Secondary (7--13 y)                                                              5348 (49.6)    950 (51.9)     1803 (51.9)            1247 (48.3)            1348 (46.7)
  Higher (\>13 y)                                                                  3497 (32.5)    625 (34.1)     1118 (32.2)            863 (33.4)             891 (30.9)
  Missing                                                                          1115           239            366                    221                    289
  Age, y                                                                           57.7 (12.1)    60.5 (12.3)    59.3 (12.0)            57.5 (12.0)            54.1 (11.3)
  Missing                                                                          0              0              0                      0                      0
  Time since diagnosis, years                                                      5.7 (5.3)      5.4 (5.2)      6.0 (5.4)              5.8 (5.1)              5.5 (5.3)
  Missing                                                                          325            81             116                    61                     67
  HbA1c, %                                                                         8.3 (1.7)      6.4 (0.4)      7.5 (0.3)              8.4 (0.3)              10.5 (1.4)
  FPG, mmol/L                                                                      9.5 (3.1)      7.1 (1.6)      8.3 (1.8)              9.6 (2.3)              12.2 (3.6)
  Missing                                                                          3207           624            1108                   722                    753
  BMI, kg/m^2^                                                                     29.4 (6.0)     29.0 (6.2)     29.1 (5.8)             29.8 (5.7)             29.7 (6.2)
  Missing                                                                          790            114            226                    184                    266
  Tobacco smoking, n (%)                                                                                                                                       
  Non‐smoker                                                                       7771 (67.0)    1284 (63.8)    2456 (65.8)            1918 (69.9)            2113 (68.1)
  Ex‐smoker                                                                        2088 (18.0)    466 (23.1)     717 (19.2)             433 (15.8)             472 (15.2)
  Current smoker                                                                   1737 (15.0)    263 (13.1)     562 (15.0)             392 (14.3)             520 (16.7)
  Missing                                                                          295            58             105                    61                     71
  SBP, mm Hg                                                                       132.6 (16.4)   131.6 (16.6)   132.6 (16.1)           133.0 (15.9)           132.9 (17.2)
  Missing                                                                          513            73             158                    109                    173
  History of microvascular disease[a](#dom13866-note-0005){ref-type="fn"}, n (%)   2567 (21.6)    444 (21.4)     812 (21.2)             575 (20.5)             736 (23.2)
  Missing                                                                          11             1              6                      2                      2
  History of macrovascular disease[b](#dom13866-note-0006){ref-type="fn"}, n (%)   1732 (14.6)    354 (17.2)     623 (16.3)             385 (13.8)             370 (11.7)
  Missing                                                                          35             8              14                     5                      8
  Received education on diabetes management in the past year, n (%)                6722 (75.0)    1057 (77.0)    2007 (72.7)            1694 (75.3)            1964 (75.9)
  NA[c](#dom13866-note-0007){ref-type="fn"}                                        1865           531            789                    304                    241
  Missing                                                                          1059           168            292                    250                    349
  Comedications, n (%)                                                                                                                                         
  ASA                                                                              2042 (17.2)    331 (16.0)     662 (17.2)             526 (18.8)             523 (16.5)
  Statins                                                                          5460 (45.9)    988 (47.7)     1834 (47.8)            1307 (46.6)            1331 (41.9)
  ACE inhibitors/ARBs                                                              4727 (39.8)    844 (40.8)     1617 (42.1)            1149 (41.0)            1117 (35.2)
  Diuretics                                                                        1421 (12.0)    275 (13.3)     476 (12.4)             350 (12.5)             320 (10.1)
  β‐blockers                                                                       1702 (14.3)    332 (16.0)     555 (14.5)             444 (15.8)             371 (11.7)
  First‐line therapy, n (%)                                                                                                                                    
  MET monotherapy                                                                  6961 (58.5)    1232 (59.5)    2398 (62.5)            1610 (57.4)            1721 (54.2)
  SU monotherapy                                                                   805 (6.8)      139 (6.7)      231 (6.0)              217 (7.7)              218 (6.9)
  DPP‐4 inhibitor monotherapy                                                      1122 (9.4)     304 (14.7)     453 (11.8)             206 (7.3)              159 (5.0)
  Other monotherapy                                                                445 (3.7)      146 (7.0)      167 (4.4)              73 (2.6)               59 (1.9)
  MET + SUs                                                                        1525 (12.8)    137 (6.6)      323 (8.4)              399 (14.2)             666 (21.0)
  MET + DPP‐4 inhibitors                                                           425 (3.6)      61 (2.9)       115 (3.0)              116 (4.1)              133 (4.2)
  MET + other[d](#dom13866-note-0008){ref-type="fn"}                               131 (1.1)      14 (0.7)       49 (1.3)               41 (1.5)               27 (0.9)
  Other combinations                                                               476 (4.0)      38 (1.8)       103 (2.7)              142 (5.1)              193 (6.1)
  Missing                                                                          1              0              1                      0                      0
  Second‐line therapy, n (%)                                                                                                                                   
  MET monotherapy                                                                  194 (1.6)      99 (4.8)       52 (1.4)               21 (0.7)               22 (0.7)
  SU monotherapy                                                                   322 (2.7)      93 (4.5)       96 (2.5)               57 (2.0)               76 (2.4)
  DPP‐4 inhibitor monotherapy                                                      531 (4.5)      210 (10.1)     194 (5.1)              78 (2.8)               49 (1.5)
  Other monotherapy                                                                348 (2.9)      96 (4.6)       106 (2.8)              81 (2.9)               65 (2.0)
  MET + SU                                                                         2227 (18.7)    280 (13.5)     684 (17.8)             585 (20.9)             678 (21.3)
  MET + DPP‐4 inhibitors                                                           3250 (27.3)    607 (29.3)     1294 (33.7)            760 (27.1)             589 (18.5)
  MET + other[c](#dom13866-note-0007){ref-type="fn"}                               1164 (9.8)     260 (12.6)     431 (11.2)             236 (8.4)              237 (7.5)
  Other combinations                                                               3131 (26.3)    394 (19.0)     904 (23.5)             843 (30.1)             990 (31.2)
  Insulin                                                                          723 (6.1)      32 (1.5)       78 (2.0)               143 (5.1)              470 (14.8)
  Missing                                                                          1              0              1                      0                      0

Data are reported as mean (SD), unless otherwise stated. Percentages are calculated for all patients with data available; missing data are excluded.

Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; DPP‐4, dipeptidyl peptidase‐4; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MET, metformin; NA, not available; SBP, systolic blood pressure; SU, sulphonylurea.

Includes nephropathy (presence of chronic kidney disease and/or albuminuria), retinopathy (history of retinopathy or retinal laser photocoagulation), and neuropathy (autonomic neuropathy, peripheral neuropathy, and erectile dysfunction).

Includes coronary artery disease (history of coronary artery disease, angina, myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting), cerebrovascular disease (stroke, transient ischaemic attack, carotid artery stenting, and carotid endarterectomy), peripheral artery disease (history of peripheral artery disease including revascularization procedures, diabetic foot, and amputation), heart failure, and implantable cardioverter defibrillator use.

These patients are from Japan, where data on diabetes education were not collected.

Excluding insulin.

3.1. Patterns of glycaemic control by country and region {#dom13866-sec-0013}
--------------------------------------------------------

Overall, HbA1c data were available for 11 891 patients (80.9%; ARR 57.5%‐98.2%), with substantial variation between countries (Tables [2](#dom13866-tbl-0002){ref-type="table"} and [3](#dom13866-tbl-0003){ref-type="table"}). FPG data were available for 70.3% of patients (ARR 36.2%‐84.5%), and 13 546 patients (92.2%) had either HbA1c or FPG data available (ARR 59.2%‐99.1%; Table [2](#dom13866-tbl-0002){ref-type="table"}). Among countries, the proportions of patients with either HbA1c or FPG measurements available ranged from 36.8% to 100.0% (Table [3](#dom13866-tbl-0003){ref-type="table"}). Reasons for changing therapy among patients with or without available HbA1c or FPG data, as well as according to country income, are shown in Table [S2](#dom13866-supitem-0001){ref-type="supplementary-material"}. In both patient populations, lack of efficacy was the most commonly stated reason for changing therapy, although this was more common in patients with HbA1c or FPG measurements than in patients without available measurements (90.5% vs 67.7% of patients). Physician preference, patient request and side effects were more commonly stated as reasons for changing therapy in patients without available HbA1c or FPG measurements than in patients with available measurements (16.5% vs 5.1%, 4.2% vs 1.3% and 6.2% vs 4.7%, respectively). Efficacy was the most commonly stated reason for choosing a second‐line therapy in both patient populations.

###### 

Glycated haemoglobin and fasting plasma glucose data and availability, by region

                                Overall         Africa       Americas      South‐East Asia   Europe        Eastern Mediterranean   Western Pacific
  ----------------------------- --------------- ------------ ------------- ----------------- ------------- ----------------------- -----------------
  Mean (SD) HbA1c, %,           8.3 (1.7)       8.6 (1.9)    8.5 (1.9)     8.6 (1.7)         8.1 (1.6)     8.7 (1.6)               7.9 (1.6)
  Mean (SD) FPG, mmol/L         9.5 (3.1)       9.7 (3.5)    9.8 (3.4)     9.3 (3.0)         9.3 (3.0)     10.2 (3.3)              8.9 (2.8)
  Availability of data, n (%)                                                                                                      
  With HbA1c data               11 891 (80.9)   467 (57.5)   1531 (76.5)   2052 (61.1)       3003 (86.3)   2046 (93.8)             2792 (97.5)
  HbA1c and FPG data            8684 (59.1)     280 (34.5)   1180 (58.9)   1706 (50.8)       2306 (66.3)   1774 (81.3)             1438 (50.2)
  HbA1c data only               3207 (21.8)     187 (23.0)   351 (17.5)    346 (10.3)        697 (20.0)    272 (12.5)              1354 (47.3)
  With FPG data only            1655 (11.3)     14 (1.7)     211 (10.5)    1030 (30.7)       285 (8.2)     70 (3.2)                45 (1.6)
  No HbA1c or FPG data          1153 (7.8)      331 (40.8)   260 (13.0)    278 (8.3)         191 (5.5)     66 (3.0)                27 (0.9)

Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.

###### 

Availability of glycated haemoglobin and fasting plasma glucose data, by country

  Region                      Country                With HbA1c and FPG data   With HbA1c data only   With FPG data only   No HbA1c or FPG data
  --------------------------- ---------------------- ------------------------- ---------------------- -------------------- ----------------------
  **Africa**                  Algeria                207 (70.6)                75 (25.6)              8 (2.7)              3 (1.0)
                              South Africa           73 (14.1)                 112 (21.6)             6 (1.2)              328 (63.2)
  **Americas**                Argentina              222 (74.2)                35 (11.7)              23 (7.7)             19 (6.4)
                              Brazil                 309 (70.7)                95 (21.7)              14 (3.2)             19 (4.3)
                              Canada                 230 (59.6)                50 (13.0)              4 (1.0)              102 (26.4)
                              Colombia               140 (68.0)                38 (18.4)              10 (4.9)             18 (8.7)
                              Costa Rica             52 (40.9)                 50 (39.4)              8 (6.3)              17 (13.4)
                              Mexico                 179 (39.3)                70 (15.4)              143 (31.4)           63 (13.8)
                              Panama                 48 (52.2)                 13 (14.1)              9 (9.8)              22 (23.9)
  **South‐East Asia**         India                  1599 (50.9)               327 (10.4)             962 (30.6)           251 (8.0)
                              Indonesia              107 (48.4)                19 (8.6)               68 (30.8)            27 (12.2)
  **Europe**                  Austria                156 (74.6)                39 (18.7)              1 (0.5)              13 (6.2)
                              Czech Republic         357 (78.6)                83 (18.3)              4 (0.9)              10 (2.2)
                              Denmark                2 (4.9)                   30 (73.2)              0 (0.0)              9 (22.0)
                              France                 204 (77.3)                40 (15.2)              4 (1.5)              16 (6.1)
                              Italy                  327 (90.6)                29 (8.0)               4 (1.1)              1 (0.3)
                              Netherlands            143 (88.3)                13 (8.0)               3 (1.9)              3 (1.9)
                              Norway                 3 (3.8)                   65 (82.3)              1 (1.3)              10 (12.7)
                              Poland                 160 (49.4)                84 (25.9)              39 (12.0)            41 (12.7)
                              Russia                 276 (46.9)                70 (11.9)              199 (33.8)           43 (7.3)
                              Spain                  195 (86.7)                16 (7.1)               10 (4.4)             4 (1.8)
                              Sweden                 16 (6.8)                  198 (83.9)             0 (0.0)              22 (9.3)
                              Turkey                 467 (87.1)                30 (5.6)               20 (3.7)             19 (3.5)
  **Eastern Mediterranean**   Bahrain                55 (78.6)                 15 (21.4)              0 (0.0)              0 (0.0)
                              Egypt                  489 (83.9)                45 (7.7)               45 (7.7)             4 (0.7)
                              Jordan                 208 (76.8)                40 (14.8)              7 (2.6)              16 (5.9)
                              Kuwait                 48 (94.1)                 3 (5.9)                0 (0.0)              0 (0.0)
                              Lebanon                277 (79.6)                54 (15.5)              2 (0.6)              15 (4.3)
                              Oman                   21 (67.7)                 10 (32.3)              0 (0.0)              0 (0.0)
                              Saudi Arabia           402 (77.5)                80 (15.4)              7 (1.3)              30 (5.8)
                              Tunisia                191 (89.3)                14 (6.5)               9 (4.2)              0 (0.0)
                              United Arab Emirates   83 (87.4)                 11 (11.6)              0 (0.0)              1 (1.1)
  **Western Pacific**         Australia              92 (55.1)                 66 (39.5)              1 (0.6)              8 (4.8)
                              Japan                  691 (37.0)                1174 (62.8)            0 (0.0)              4 (0.2)
                              Malaysia               257 (76.9)                32 (9.6)               37 (11.1)            8 (2.4)
                              Korea, South           163 (69.1)                68 (28.8)              2 (0.8)              3 (1.3)
                              Taiwan                 235 (91.1)                14 (5.4)               5 (1.9)              4 (1.6)

Data are reported as n (%).

Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.

The overall mean (SD; ARR) HbA1c level at initiation of second‐line therapy was 8.3 (1.7; 7.9‐8.7)% (Table [2](#dom13866-tbl-0002){ref-type="table"}). Mean HbA1c levels were highest in the Eastern Mediterranean region and lowest in the Western Pacific region (8.7% and 7.9%, respectively). The overall proportions of patients with HbA1c \<8.0%, ≥8.0 to \<9.0% and ≥9.0% were 49.8%, 23.6% and 26.7%, respectively. These proportions varied across countries and regions (Figure [1](#dom13866-fig-0001){ref-type="fig"}).

![Proportions of patients in different glycated haemoglobin ranges at initiation of second‐line therapy. UAE, United Arab Emirates](DOM-22-66-g001){#dom13866-fig-0001}

As expected in a population of patients initiating second‐line glucose‐lowering therapy, the overall proportion of patients with HbA1c \<7.0% among patients with available values was low (17.4%, ARR 9.6%‐25.8%; Figure [1](#dom13866-fig-0001){ref-type="fig"}). The mean (SD) HbA1c among these patients was 6.4 (0.4)% (Table [1](#dom13866-tbl-0001){ref-type="table"}), and the reasons for changing therapy are presented in Table [S3](#dom13866-supitem-0001){ref-type="supplementary-material"}. As in the overall cohort, the majority of patients (72.3%) with HbA1c \<7.0% changed first‐line therapy owing to lack of efficacy (ARR 56.9%‐85.8%). The most common reasons for choosing a second‐line therapy were expected efficacy (39.7%, ARR 15.4%‐70.8%) and tolerability (22.7%, ARR 5.3%‐36.2%). The proportion of patients with HbA1c \<7.0% was particularly low in Africa (12.2%), South‐East Asia (13.4%), and the Eastern Mediterranean region (9.6%), and was highest in Europe and the Western Pacific region (18.7% and 25.8%, respectively). The proportion of patients with HbA1c ≥9.0% varied substantially across regions, with the highest proportions in South‐East Asia (35.6%) and the Eastern Mediterranean region (33.9%). In total, 19 countries had \>25% of patients with HbA1c ≥9.0% at initiation of second‐line therapy.

3.2. Factors associated with poor glycaemic control at initiation of second‐line therapy {#dom13866-sec-0014}
----------------------------------------------------------------------------------------

Figure [2](#dom13866-fig-0002){ref-type="fig"} shows the factors associated with poor glycaemic control, defined as HbA1c \>8.0%, at initiation of second‐line therapy. In this model, young patients were more likely to have poor glycaemic control at the time of treatment intensification than old patients, and the odds of having poor glycaemic control decreased with each 10‐year age increment. The following factors were also associated with poor glycaemic control: male sex; having a low level of education versus \>13 years of formal education; being a current smoker; having high SBP (per 10 mm Hg increment); having a time since T2D diagnosis of \>10 years; not taking statins; receiving sulphonylurea (SU) monotherapy, an SU or dipeptidylpeptidase‐4 (DPP‐4) inhibitor in combination with metformin or another combination of two or more agents as first‐line treatment, versus metformin; and having a history of microvascular complications. Additionally, patients in lower‐middle‐income countries were more likely to have HbA1c levels \>8.0% than patients from high‐income countries. Results of analyses using thresholds of 7.0% or 9.0% to define poor glycaemic control (Figure [S2](#dom13866-supitem-0001){ref-type="supplementary-material"}) were similar to those of the primary analysis. There was no significant association between receiving education on diabetes management in the past year and the likelihood of having HbA1c levels \>8.0%, when assessed in patients for whom this information was collected (Figure [S3](#dom13866-supitem-0001){ref-type="supplementary-material"}).

![Multivariate analysis of factors associated with poor glycaemic control defined as glycated haemoglobin (HbA1c) \>8.0%. ^†^The plot shows odds ratios, adjusted for all variables in the figure, using a hierarchical logistic model as described in the methods. HbA1c is modelled as a dichotomous variable. ^‡^Includes nephropathy (presence of chronic kidney disease and/or albuminuria), retinopathy (history of retinopathy or retinal laser photocoagulation), and neuropathy (autonomic neuropathy, peripheral neuropathy, and erectile dysfunction). ^§^Includes coronary artery disease (history of coronary artery disease, angina, myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting), cerebrovascular disease (stroke, transient ischaemic attack, carotid artery stenting, and carotid endarterectomy), peripheral artery disease (history of peripheral artery disease including revascularization procedures, diabetic foot, and amputation), heart failure, and implantable cardioverter defibrillator use. ^¶^Categorized using the 2016 World Bank classification. ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CI, confidence interval; DPP‐4, dipeptidyl peptidase‐4; MET, metformin; mono, monotherapy; OR, odds ratio; SBP, systolic blood pressure; SU, sulphonylureas; T2D, type 2 diabetes](DOM-22-66-g002){#dom13866-fig-0002}

4. DISCUSSION {#dom13866-sec-0015}
=============

The present analysis of data from the DISCOVER study programme revealed consistently high HbA1c levels at initiation of second‐line therapy across countries and regions worldwide. Approximately 50% of patients with available HbA1c measurements had HbA1c \>8.0%, and \>25% had HbA1c \>9.0%. Overall, \<20% of patients had HbA1c \<7.0%. Many patients did not have available HbA1c measurements, despite a decision to initiate second‐line therapy having been made, which highlights an opportunity for improvement of the quality of care of patients with T2D.

Although previous studies have reported poor levels of glycaemic control among patients with T2D,[22](#dom13866-bib-0022){ref-type="ref"}, [23](#dom13866-bib-0023){ref-type="ref"}, [24](#dom13866-bib-0024){ref-type="ref"} these have mostly been conducted in populations of patients with more advanced disease than in the present study. For example, the A~1~chieve study[25](#dom13866-bib-0025){ref-type="ref"} was a global, prospective, observational study of patients with T2D who were initiating insulin therapies in routine clinical practice. That study included patients from 30 countries across four continents (Asia, Africa, South America and Europe); 21 of these countries were included in DISCOVER. In A~1~chieve, the mean baseline HbA1c was higher than that in DISCOVER participants (9.5% vs 8.3%), which is likely to reflect the more severe diabetic phenotype in patients who are initiating insulin therapies. Similarly, the IMPROVE study, which included \>50 000 patients across eight countries with a mean diabetes duration of 6.9 years, reported a mean HbA1c of 9.4%.[26](#dom13866-bib-0026){ref-type="ref"} In the multinational, prospective International Diabetes Management Practice Study (IDMPS) survey, the mean HbA1c and mean diabetes duration were 7.8% and 8.4 years, respectively, among patients with T2D.[11](#dom13866-bib-0011){ref-type="ref"} The IDMPS study cohort comprised 9901 patients with T2D from Asia (Korea, China, Indonesia, India, Hong Kong, Taiwan, Malaysia and Thailand), Eastern Europe (Romania, Bulgaria, Turkey, Tunisia and Bosnia), Latin America (Argentina, Ecuador, Venezuela and Columbia), and Africa (Tunisia), many of whom were receiving insulin therapy. In the context of these studies of patients with presumably more severe diabetes than patients in the present study, the poor overall glycaemic control among DISCOVER patients is concerning.

The mean HbA1c at initiation of second‐line therapy and the proportion of patients with HbA1c ≥9.0% were generally higher in lower‐middle‐ and upper‐middle‐income countries than in high‐income countries. Particularly concerning regions were parts of Asia and Africa, as well as the Middle‐Eastern region. Consistent with this finding, results from the multivariate analysis showed that living in a lower‐middle‐income country was strongly associated with poor glycaemic control (HbA1c \>8.0%) relative to living in a high‐income country; this result was also seen when a threshold of 9.0% was used in the analysis. This was not unexpected, given that low income is likely to translate into reduced expenditure on healthcare. Indeed, many of the countries included in DISCOVER have very low diabetes‐related healthcare expenditure compared with high‐income countries.[27](#dom13866-bib-0027){ref-type="ref"} Likely consequences of this low expenditure on care for patients with T2D include a lack of resources for HbA1c monitoring, which may lead to delays in intensifying second‐line glucose‐lowering therapies. Consistent with this hypothesis, over one‐third of patients in the South‐East Asia and African regions lacked HbA1c measurements in the present study. These findings are consistent with those from the IDMPS survey, which revealed that 36% of patients with T2D in developing regions had never had their HbA1c levels measured.[11](#dom13866-bib-0011){ref-type="ref"} Similarly, the authors of a study conducted in Brazil commented that kits for HbA1c measurement are not routinely provided by the National Brazilian Health Care System.[28](#dom13866-bib-0028){ref-type="ref"} Aside from HbA1c monitoring, patients in lower‐middle and upper‐middle‐income countries may also encounter problems with the availability and affordability of glucose‐lowering therapies compared with patients in high‐income countries.[29](#dom13866-bib-0029){ref-type="ref"} Indeed, in the present study, physicians cited cost and access to treatment as reasons for choosing second‐line therapy for 7.2% and 5.1% of patients, respectively, and these proportions were higher in middle‐income countries than in high‐income countries.

Mean levels of HbA1c were also well above guideline‐recommended values in many high‐income countries. As with lower‐middle and upper‐middle‐income countries, this finding may reflect delays in treatment intensification but for different reasons. A possible contributing factor is conservative management of patients by clinicians, as has been documented previously.[16](#dom13866-bib-0016){ref-type="ref"}, [30](#dom13866-bib-0030){ref-type="ref"} In addition, the current stepwise approach to treatment intensification that is advocated by major treatment guidelines may lead to prolonged periods of hyperglycaemia in between steps.[15](#dom13866-bib-0015){ref-type="ref"}, [31](#dom13866-bib-0031){ref-type="ref"} A recent analysis of patients in the United States showed no improvements in overall glycaemic control and an increase in the proportion of patients with HbA1c ≥9.0% between 2006 and 2013, despite increased utilization of newer and costlier glucose‐lowering agents among these patients.[32](#dom13866-bib-0032){ref-type="ref"} These data, combined with the present data, highlight a pressing need to re‐evaluate existing treatment pathways for patients with T2D in order to improve glycaemic control.

Other factors associated with poor glycaemic control in multivariate analyses included younger age, male sex, low education level, and use of combination glucose‐lowering therapies as first‐line diabetes treatment. The inverse relationship between age and glycaemic control, while somewhat counter‐intuitive, might be explained by older patients being monitored more closely by physicians than younger patients, owing to their increased comorbidity and heightened risk of complications. Authors of other studies have also hypothesized that older patients might be more motivated to look after their health and adhere to their medications than young patients.[33](#dom13866-bib-0033){ref-type="ref"} Patients with a high level of education are likely to have better means to fund treatment or private medical care than less educated patients, and there is some evidence of a correlation between education level and the quality of diabetes care and outcomes.[34](#dom13866-bib-0034){ref-type="ref"} This hypothesis is also consistent with the association seen in our data between lower country income and poor glycaemic control. As might be expected, having a time since diagnosis of T2D of at least 10 years compared with 0 to 5 years was also strongly correlated with poor glycaemic control. This finding is consistent with other observational studies that have demonstrated a positive relationship between disease duration and poor glycaemic control.[35](#dom13866-bib-0035){ref-type="ref"}, [36](#dom13866-bib-0036){ref-type="ref"} The trend is likely to reflect the continual decline in β‐cell function that is characteristic of T2D. These findings emphasize the importance of intensifying treatment in a timely manner once HbA1c is no longer controlled by first‐line therapy.

The positive association between use of combination glucose‐lowering therapy as first‐line treatment and poor glycaemic control is probably explained by the fact that patients with high HbA1c levels at the time of diagnosis require more intensive pharmacological treatment than patients with lower HbA1c levels, as per clinical guideline recommendations.[6](#dom13866-bib-0006){ref-type="ref"} However, these intensive treatments may fail to control glycaemia adequately, which is why HbA1c levels could remain high and require initiation of second‐line therapy. As described previously,[21](#dom13866-bib-0021){ref-type="ref"}, [37](#dom13866-bib-0037){ref-type="ref"} our findings also showed a positive association between having a history of microvascular complications and having HbA1c levels \>8.0%. This finding is consistent with evidence that intensive glycaemic control for a prolonged period decreases the incidence of microvascular complications.[37](#dom13866-bib-0037){ref-type="ref"} However, longitudinal data from DISCOVER are required to confirm a relationship between changes in HbA1c trajectories and the incidence of diabetes complications in the present study cohort.

An interesting finding in the present study was that close to 20% of patients in the study cohort had HbA1c \<7.0%. This was somewhat unexpected, given that this is a population of patients who are initiating second‐line glucose‐lowering therapy. The finding that the majority of these patients cited efficacy as the reason for changing treatment was also surprising, although it is notable that this proportion of patients was lower than in the overall population of patients with available HbA1c or FPG measurements. Similarly, although almost half of patients with HbA1c \<7.0% cited efficacy as a reason for choosing a second‐line therapy, this was lower than in the overall patient population. It could be the case that the patients with HbA1c \<7.0% in the present study were early in their disease trajectory and therefore had been set HbA1c targets below 7.0% by their physicians, consistent with guideline recommendations for patients with few comorbidities and low risk of hypoglycaemia.[7](#dom13866-bib-0007){ref-type="ref"}

Within the study cohort, there were large numbers of patients without available data on the extent of glycaemic control. As highlighted previously, this was particularly evident in lower‐middle and upper‐middle‐income countries in which physicians may not monitor HbA1c levels routinely, owing to the high cost of this practice compared with obtaining other measures of glycaemic control. Many patients who lacked HbA1c data in the present cohort had FPG data instead, which suggests that FPG may be used as an alternative to HbA1c to monitor glycaemia and to support treatment change decisions in some countries. While there is some evidence to suggest a good correlation between HbA1c and FPG measurements within a certain range,[38](#dom13866-bib-0038){ref-type="ref"} this practice is contradictory to treatment guidelines. Overall, 7.8% of the cohort had neither HbA1c nor FPG data available, and this proportion was particularly high (40.8%) in the African region. It is concerning that in some countries, 10% to 20% of patients switched glucose‐lowering therapy in the absence of FPG or HbA1c measurements to direct this decision. Although one might expect that this would be due to concerns about cost or tolerability, it is notable that the proportions of patients for whom these factors were recorded as reasons for changing therapy were low, despite being slightly higher in patients without FPG or HbA1c measurements than in patients for whom these measurements were available.

Key strengths of the DISCOVER study programme include the large numbers of patients and inclusion of many lower‐middle and upper‐middle‐income countries which have rarely or never been studied before.[17](#dom13866-bib-0017){ref-type="ref"} The use of a standardized electronic case report form for data collection allows comparison of results within and across countries and regions. As DISCOVER is a longitudinal study, data collected during follow‐up will provide valuable insights into the relationship between glycaemic control and clinical outcomes in patients with T2D across the globe. The results reported in this manuscript provide context for the interpretation of these follow‐up data. There are also potential limitations of DISCOVER. Although study sites were selected with the intention of providing a patient population that was as representative of T2D care in each country as possible,[19](#dom13866-bib-0019){ref-type="ref"} attainment of a truly representative sample is inherently difficult to achieve in large international studies. Reasons for this include infrastructure challenges, and the fact that some primary care centres are not set up for or willing to participate in observational research. Such practical constraints resulted in urban locations and secondary care centres being over‐represented in this study. Moreover, levels of education seen in our patient population are higher on average than would be expected. This potential selection bias is likely to lead to an over‐estimation of the quality of diabetes care, since better‐educated patients in urban locations would be expected to receive better healthcare than less educated patients in rural locations.[19](#dom13866-bib-0019){ref-type="ref"} Thus, the level of glycaemic control at initiation of second‐line treatment across the DISCOVER countries may be even worse than the findings reported in the present study. Despite these limitations, the efforts made to maximize representativeness resulted in the inclusion of a heterogeneous patient population, as well as a diverse range of sites and physicians. Overall, ethnicity and sex distributions of DISCOVER patients were in agreement with corresponding data from the 2017 Atlas of the International Diabetes Federation.[19](#dom13866-bib-0019){ref-type="ref"} The high proportion of missing data in several countries, which might have reduced the precision of the multivariate analysis where imputation was used to compensate for unreported data, should also be acknowledged. However, this is likely to be reflective of routine clinical care; for example, HbA1c is not routinely measured in some clinical settings.

In conclusion, data from the DISCOVER study confirmed that therapeutic inertia is a global phenomenon with consistently high HbA1c levels at initiation of second‐line glucose‐lowering therapy, particularly in lower‐middle and upper‐middle‐income countries. Globally, there are large numbers of patients with very poor glycaemic control (HbA1c ≥9.0%) at initiation of second‐line glucose‐lowering therapy, suggesting that treatment is not intensified in a timely manner as recommended by clinical guidelines. Factors associated with poor glycaemic control included low education level, low country income, and longer time since diagnosis of diabetes. Despite guideline recommendations, HbA1c was not routinely measured in all countries, perhaps owing to the higher cost of HbA1c measurements in lower‐middle‐income countries than in high‐income countries. These findings suggest a need for better monitoring of glycaemic control in patients with T2D worldwide, as well as interventions to improve HbA1c control at early stages of the disease.
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